Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Nov
29
Today In Oncology
FDA Approves Durvalumab With FLOT for Resectable Gastric-GEJ Adenocarcinoma
AI Simplifies Patients Comprehension of CT Reports But Are Errors Possible
External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer
No Overall Survival Benefit for Lenvatinib in LEAP-014 Trial of Esophageal Cancer
ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo